We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TLPH:NASDAQTalphera, Inc. Analysis

Data as of 2026-08-31 - not real-time

$1.19

Latest Price

9/10Risk

Risk Level: High

Executive Summary

The moving-average structure behind Talphera, Inc. is bullish at $1.19, with short-term averages leading the long-term ones. It has lost 7.8% over the past 30 days. Momentum indicators put RSI at 43.2 (neutral) with MACD reading bearish. Watch $1.11 as support and $1.50 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 166.1% above today's level.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 65.9%, a beta of 1.27 and a maximum drawdown of 50.7%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.

Top Market Events

SAN MATEO, Calif. AP — SAN MATEO, Calif. AP — Talphera, Inc. TLPH on Wednesday reported a loss of $4.3 million in...Updated Aug 12, 2026 0 NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year...Talphera, Inc. Nasdaq: TLPH , "Talphera" , a specialty pharmaceutical company focused on the development and...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 1.03
  • MACD momentum is negative

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 1.03
  • Analyst targets imply +166.1% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • Analyst targets imply +166.1% versus the current price
  • Negative return on equity of -143.4%
  • Negative free cash flow

Key Metrics & Analysis

Financial Health

P/E Ratio-4.9
ROE-143.36%
ROA-42.55%
Debt/Equity45.11
P/B Ratio3.2
Op. Cash Flow$-12270000
Free Cash Flow$-6870875
Industry P/E30.4

Technical Analysis

TrendBullish
RSI43.2
Support$1.11
Resistance$1.50
MA 20$1.28
MA 50$1.26
MA 200$1.03
MACDBearish
VolumeDecreasing
Fear & Greed Index94.55

Valuation

Target Price$3.17
Upside/Downside166.11%
GradeFair
TypeBlend

Risk Assessment

Beta1.27
Volatility65.95%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.